The stock of Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) last traded at $0.07, down -3.31% from the previous session.
Data from the available sources indicates that Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) is covered by 1 analysts. The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $3149.49 and a low of $3149.49, we find $3149.49. Given the previous closing price of $0.07, this indicates a potential upside of 4499171.43 percent. BDRX stock price is now -57.94% away from the 50-day moving average and -98.08% away from the 200-day moving average. The market capitalization of the company currently stands at $4.51M.
In total, 1 analysts have assigned it a hold rating, and 0 have given it a buy rating. Brokers who have rated the stock have averaged $3149.49 as their price target over the next twelve months.
There have been several recent changes in the stakes of large investors in BDRX stock. A new stake in Biodexa Pharmaceuticals Plc shares was purchased by VIRTU FINANCIAL LLC during the first quarter worth $3,000. MILLENNIUM MANAGEMENT LLC invested $3,000 in shares of BDRX during the first quarter. In the first quarter, CVI HOLDINGS, LLC acquired a new stake in Biodexa Pharmaceuticals Plc valued at approximately $2,000. KINGSVIEW WEALTH MANAGEMENT, LLC acquired a new stake in BDRX for approximately $1,000. In total, there are 9 active investors with 5.30% ownership of the company’s stock.
With an opening price of $0.0695 on Thursday morning, Biodexa Pharmaceuticals Plc (NASDAQ: BDRX) set off the trading day. During the past 12 months, Biodexa Pharmaceuticals Plc has had a low of $0.06 and a high of $20.80. As of last week, the company has a debt-to-equity ratio of 0.20, a current ratio of 2.50, and a quick ratio of 2.50. The fifty day moving average price for BDRX is $0.1635 and a two-hundred day moving average price translates $3.5435 for the stock.
The latest earnings results from Biodexa Pharmaceuticals Plc (NASDAQ: BDRX) was released for Dec, 2022. For the current quarter, analysts expect BDRX to generate $240k in revenue.
Biodexa Pharmaceuticals Plc(BDRX) Company Profile
Biodexa Pharmaceuticals Plc, a drug delivery technology company, focuses on the bio-delivery and biodistribution of medicines in Belgium and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and MTX223, a long-acting injectable formulations of biologic products, such as mAbs or other high molecular weight proteins. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
